Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bridges

Showing results (321-330 of 403) with videos related to

Pageof 41
Sort By:
Pharmacology Research & Perspectives|December 14, 2019
MrgX2 is a promiscuous receptor for basic peptides causing mast cell pseudo-allergic and anaphylactoid reactionsJak Grimes, Sapna Desai, Neil W Charter, et al.
ACS Chemical Neuroscience|February 21, 2025
Discovery of ONO-2920632 (VU6011887): A Highly Selective and CNS Penetrant TREK-2 (TWIK-Related K+ Channel 2) Preferring Activator <i>In Vivo</i> Tool CompoundKentaro Yashiro, Yuzo Iwaki, Hirohito Urata, et al.
Journal of Medicinal Chemistry|September 5, 2003
CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approachTheo A Berkhout, Frank E Blaney, Angela M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|January 4, 2011
Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probePaul R Reid, Thomas M Bridges, Douglas J Sheffler, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 6, 2008
Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in ratsAshley E Brady, Carrie K Jones, Thomas M Bridges, et al.
Journal of Medicinal Chemistry|August 23, 2014
Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380)Patrick R Gentry, Masaya Kokubo, Thomas M Bridges, et al.
BMC Bioinformatics|October 16, 2010
Integrated database for identifying candidate genes for Aspergillus flavus resistance in maizeRowena Y Kelley, Cathy Gresham, Jonathan Harper, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2012
Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012Bruce J Melancon, Thomas J Utley, Christian Sevel, et al.
Investigative Ophthalmology & Visual Science|January 26, 2018
Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for RetinoblastomaAnthony B Daniels, Michael T Froehler, Janene M Pierce, et al.
Bioorganic & Medicinal Chemistry Letters|December 1, 2019
Discovery of a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide M<sub>4</sub> positive allosteric modulator (PAM) chemotypeKayla J Temple, Julie L Engers, Madeline F Long, et al.
Pageof 41

Showing results (321-330 of 403) with videos related to

Sort By:
Pageof 41
Pharmacology Research & Perspectives|December 14, 2019
MrgX2 is a promiscuous receptor for basic peptides causing mast cell pseudo-allergic and anaphylactoid reactionsJak Grimes, Sapna Desai, Neil W Charter, et al.
ACS Chemical Neuroscience|February 21, 2025
Discovery of ONO-2920632 (VU6011887): A Highly Selective and CNS Penetrant TREK-2 (TWIK-Related K+ Channel 2) Preferring Activator <i>In Vivo</i> Tool CompoundKentaro Yashiro, Yuzo Iwaki, Hirohito Urata, et al.
Journal of Medicinal Chemistry|September 5, 2003
CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approachTheo A Berkhout, Frank E Blaney, Angela M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|January 4, 2011
Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probePaul R Reid, Thomas M Bridges, Douglas J Sheffler, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 6, 2008
Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in ratsAshley E Brady, Carrie K Jones, Thomas M Bridges, et al.
Journal of Medicinal Chemistry|August 23, 2014
Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380)Patrick R Gentry, Masaya Kokubo, Thomas M Bridges, et al.
BMC Bioinformatics|October 16, 2010
Integrated database for identifying candidate genes for Aspergillus flavus resistance in maizeRowena Y Kelley, Cathy Gresham, Jonathan Harper, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2012
Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012Bruce J Melancon, Thomas J Utley, Christian Sevel, et al.
Investigative Ophthalmology & Visual Science|January 26, 2018
Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for RetinoblastomaAnthony B Daniels, Michael T Froehler, Janene M Pierce, et al.
Bioorganic & Medicinal Chemistry Letters|December 1, 2019
Discovery of a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide M<sub>4</sub> positive allosteric modulator (PAM) chemotypeKayla J Temple, Julie L Engers, Madeline F Long, et al.
Pageof 41